keyword
MENU ▼
Read by QxMD icon Read
search

SIOP

keyword
https://www.readbyqxmd.com/read/28383760/nephrogenic-rests-in-wilms-tumors-treated-with-preoperative-chemotherapy-the-uk-siop-wilms-tumor-2001-trial-experience
#1
Gordan M Vujanić, John R Apps, Veronica Moroz, Federica Ceroni, Richard D Williams, Neil J Sebire, Kathy Pritchard-Jones
BACKGROUND: Nephrogenic rests (NRs) are abnormally persistent foci of embryonal cells, thought to be the precursor lesion of Wilms tumors (WTs). To date, their presence has not been systematically examined in WTs treated with preoperative chemotherapy. METHODS: A systematic analysis of the data on NRs in WTs treated with preoperative chemotherapy obtained from the UK cohort of the International Society of Pediatric Oncology (SIOP) WT 2001 Trial. The study was based on central pathology review of full sets of slides from pathological specimens, with a median of 28 slides reviewed per case...
April 6, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28333999/validation-of-questionnaire-reported-hearing-with-medical-records-a-report-from-the-swiss-childhood-cancer-survivor-study
#2
Annette Weiss, Grit Sommer, Rahel Kuonen, Katrin Scheinemann, Michael Grotzer, Martin Kompis, Claudia E Kuehni
BACKGROUND: Hearing loss is a potential late effect after childhood cancer. Questionnaires are often used to assess hearing in large cohorts of childhood cancer survivors and it is important to know if they can provide valid measures of hearing loss. We therefore assessed agreement and validity of questionnaire-reported hearing in childhood cancer survivors using medical records as reference. PROCEDURE: In this validation study, we studied 361 survivors of childhood cancer from the Swiss Childhood Cancer Survivor Study (SCCSS) who had been diagnosed after 1989 and had been exposed to ototoxic cancer treatment...
2017: PloS One
https://www.readbyqxmd.com/read/28259608/busulfan-and-melphalan-versus-carboplatin-etoposide-and-melphalan-as-high-dose-chemotherapy-for-high-risk-neuroblastoma-hr-nbl1-siopen-an-international-randomised-multi-arm-open-label-phase-3-trial
#3
Ruth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklós Garami, Toby Trahair, Adela Canete, Peter F Ambros, Keith Holmes, Mark Gaze, Günter Schreier, Alberto Garaventa, Gilles Vassal, Jean Michon, Dominique Valteau-Couanet
BACKGROUND: High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however, which regimen has the greatest patient benefit has not been established. We aimed to assess event-free survival after high-dose chemotherapy with busulfan and melphalan compared with carboplatin, etoposide, and melphalan. METHODS: We did an international, randomised, multi-arm, open-label, phase 3 cooperative group clinical trial of patients with high-risk neuroblastoma at 128 institutions in 18 countries that included an open-label randomised arm in which high-dose chemotherapy regimens were compared...
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28205365/paratesticular-rhabdomyosarcoma-in-children-and-adolescents-outcome-and-patterns-of-relapse-when-utilizing-a-nonsurgical-strategy-for-lymph-node-staging-report-from-the-international-society-of-paediatric-oncology-siop-malignant-mesenchymal-tumour-89-and-95
#4
Timothy Rogers, Veronique Minard-Colin, Nathalie Cozic, Meriel Jenney, Johannes H M Merks, Soledad Gallego, Christine Devalck, Mark N Gaze, Anna Kelsey, Odile Oberlin, Mike Stevens, Richard D Spicer, Christophe Bergeron, Helene Martelli
PURPOSE: To report the results from International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumors studies (MMT 89 and 95) of males with nonmetastatic paratesticular rhabdomyosarcoma. METHODS: From 1989 to 2003, 159 patients were included. Radical inguinal orchidectomy was recommended, but retroperitoneal lymph node (LN) assessment was based on imaging alone. The treatment was stratified by stage (SIOP tumor-node-metastasis staging system) and histology...
February 16, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28161497/survival-benefit-for-patients-with-diffuse-intrinsic-pontine-glioma-dipg-undergoing-re-irradiation-at-first-progression-a-matched-cohort-analysis-on-behalf-of-the-siop-e-hgg-dipg-working-group
#5
Geert O Janssens, Lorenza Gandola, Stephanie Bolle, Henry Mandeville, Monica Ramos-Albiac, Karen van Beek, Helen Benghiat, Bianca Hoeben, Andres Morales La Madrid, Rolf-Dieter Kortmann, Darren Hargrave, Johan Menten, Emilia Pecori, Veronica Biassoni, Andre O von Bueren, Dannis G van Vuurden, Maura Massimino, Dominik Sturm, Max Peters, Christof M Kramm
BACKGROUND: Overall survival (OS) of patients with diffuse intrinsic pontine glioma (DIPG) is poor. The purpose of this study is to analyse benefit and toxicity of re-irradiation at first progression. METHODS: At first progression, 31 children with DIPG, aged 2-16 years, underwent re-irradiation (dose 19.8-30.0 Gy) alone (n = 16) or combined with systemic therapy (n = 15). At initial presentation, all patients had typical symptoms and characteristic MRI features of DIPG, or biopsy-proven high-grade glioma...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28110411/development-of-the-siope-dipg-network-registry-and-imaging-repository-a-collaborative-effort-to-optimize-research-into-a-rare-and-lethal-disease
#6
Sophie E M Veldhuijzen van Zanten, Joshua Baugh, Brooklyn Chaney, Dennis De Jongh, Esther Sanchez Aliaga, Frederik Barkhof, Johan Noltes, Ruben De Wolf, Jet Van Dijk, Antonio Cannarozzo, Carin M Damen-Korbijn, Jan A Lieverst, Niclas Colditz, Marion Hoffmann, Monika Warmuth-Metz, Brigitte Bison, David T W Jones, Dominik Sturm, Gerrit H Gielen, Chris Jones, Esther Hulleman, Raphael Calmon, David Castel, Pascale Varlet, Géraldine Giraud, Irene Slavc, Stefaan Van Gool, Sandra Jacobs, Filip Jadrijevic-Cvrlje, David Sumerauer, Karsten Nysom, Virve Pentikainen, Sanna-Maria Kivivuori, Pierre Leblond, Natasha Entz-Werle, Andre O von Bueren, Antonis Kattamis, Darren R Hargrave, Péter Hauser, Miklos Garami, Halldora K Thorarinsdottir, Jane Pears, Lorenza Gandola, Giedre Rutkauskiene, Geert O Janssens, Ingrid K Torsvik, Marta Perek-Polnik, Maria J Gil-da-Costa, Olga Zheludkova, Liudmila Shats, Ladislav Deak, Lidija Kitanovski, Ofelia Cruz, Andres Morales La Madrid, Stefan Holm, Nicolas Gerber, Rejin Kebudi, Richard Grundy, Enrique Lopez-Aguilar, Marta Zapata-Tarres, John Emmerik, Tim Hayden, Simon Bailey, Veronica Biassoni, Maura Massimino, Jacques Grill, William P Vandertop, Gertjan J L Kaspers, Maryam Fouladi, Christof M Kramm, Dannis G van Vuurden
Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in survival. It is therefore time for international collaboration in DIPG research, to provide new hope for children, parents and medical professionals fighting DIPG. In a first step towards collaboration, in 2011, a network of biologists and clinicians working in the field of DIPG was established within the European Society for Paediatric Oncology (SIOPE) Brain Tumour Group: the SIOPE DIPG Network...
April 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28061436/multidrug-resistance-transporter-profile-reveals-mdr3-as-a-marker-for-stratification-of-blastemal-wilms-tumour-patients
#7
Lourdes Hontecillas-Prieto, Daniel J Garcia-Dominguez, Diego Pascual Vaca, Rosa Garcia-Mejias, David Marcilla, Gema L Ramirez-Villar, Carmen Saez, Enrique de Álava
Wilms tumour (WT) is the most common renal tumour in children. Most WT patients respond to chemotherapy, but subsets of tumours develop resistance to chemotherapeutic agents, which is a major obstacle in their successful treatment. Multidrug resistance transporters play a crucial role in the development of resistance in cancer due to the efflux of anticancer agents out of cells. The aim of this study was to explore several human multidrug resistance transporters in 46 WT and 40 non-neoplastic control tissues (normal kidney) from patients selected after chemotherapy treatment SIOP 93-01, SIOP 2001...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28049570/access-to-essential-medicines-for-children-with-cancer-a-joint-siop-cci-position-statement
#8
Avram Denburg, Brijesh Arora, Ramandeep Singh Arora, Carmen Auste, Poonam Bagai, Ronald Barr, Julia Challinor, Tim Eden, Edith Grynzspancholc, Ruth Hoffman, Michael Link
No abstract text is available yet for this article.
January 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28011926/evaluation-of-age-dependent-treatment-strategies-for-children-and-young-adults-with-pineoblastoma-analysis-of-pooled-european-society-for-paediatric-oncology-siop-e-and-us-head-start-data
#9
Martin Mynarek, Barry Pizer, Christelle Dufour, Dannis van Vuurden, Miklos Garami, Maura Massimino, Jason Fangusaro, Tom Davidson, Maria Joao Gil-da-Costa, Jaroslav Sterba, Martin Benesch, Nicolas Gerber, B Ole Juhnke, Robert Kwiecien, Torsten Pietsch, Marcel Kool, Steve Clifford, David W Ellison, Felice Giangaspero, Pieter Wesseling, Floyd Gilles, Nicholas Gottardo, Jonathan L Finlay, Stefan Rutkowski, Katja von Hoff
Background.: Pineoblastoma is a rare pineal region brain tumor. Treatment strategies have reflected those for other malignant embryonal brain tumors. Patients and Methods.: Original prospective treatment and outcome data from international trial groups were pooled. Cox regression models were developed considering treatment elements as time-dependent covariates. Results.: Data on 135 patients with pineoblastoma aged 0.01-20.7 (median 4.9) years were analyzed...
April 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/27969569/biology-and-treatment-of-renal-tumours-in-childhood
#10
REVIEW
Jesper Brok, Taryn D Treger, Saskia L Gooskens, Marry M van den Heuvel-Eibrink, Kathy Pritchard-Jones
In Europe, almost 1000 children are diagnosed with a malignant renal tumour each year. The vast majority of cases are nephroblastoma, also known as Wilms' tumour (WT). Most children are treated according to Société Internationale d'Oncologie Pédiatrique Renal Tumour Study Group (SIOP-RTSG) protocols with pre-operative chemotherapy, surgery, and post-operative treatment dependent on stage and histology. Overall survival approaches 90%, but a subgroup of WT, with high-risk histology and/or relapsed disease, still have a much poorer prognosis...
October 28, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27937095/group-wide-prospective-study-of-ototoxicity-assessment-in-children-receiving-cisplatin-chemotherapy-accl05c1-a-report-from-the-children-s-oncology-group
#11
Kristin R Knight, Lu Chen, David Freyer, Richard Aplenc, Mary Bancroft, Bonnie Bliss, Ha Dang, Biljana Gillmeister, Eleanor Hendershot, Dale F Kraemer, Lanie Lindenfeld, Jane Meza, Edward A Neuwelt, Brad H Pollock, Lillian Sung
Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. Patients and Methods Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment...
February 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27922041/paediatric-renal-tumours-perspectives-from-the-siop-rtsg
#12
(no author information available yet)
The >90% rates of overall survival for children with Wilms tumour are remarkable and have been achieved at the same time as reducing treatment for most patients. However, beneath this headline figure, 20% of patients still relapse after first-line therapy and up to 25% of survivors report severe late effects. The aim of the SIOP-RTSG is to improve outcomes and to reduce acute and late treatment toxic effects in all children.
January 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27898175/interventions-for-promoting-participation-in-shared-decision-making-for-children-with-cancer
#13
REVIEW
Imelda Coyne, Dónal P O'Mathúna, Faith Gibson, Linda Shields, Edith Leclercq, Greg Sheaf
BACKGROUND: This is an update of the Cochrane systematic review of shared decision-making (SMD) making published in 2013. Children's rights to have their views heard in matters that affect their lives are now well established since the publication of the UN Convention treaty (1989). Children with cancer generally prefer to be involved in decision-making and consider it important that they have the opportunity to take part in decision-making concerning their health care, even in end-of-life decisions...
November 29, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27866682/-adolescent-and-young-adults-ayas-brain-tumor-national-web-conference-on-behalf-of-anocef-go-aja-and-sfce-societies
#14
Didier Frappaz, Marie-Pierre Sunyach, Emilie Le Rhun, Marie Blonski, Valérie Laurence, Alice Bonneville Levard, Hugues Loiseau, David Meyronnet, Arnaud Callies, F Laigle-Donadey, Cecile Faure Conter
The skills of adult versus pediatric neuro-oncologists are not completely similar though additive. Because the tumors and their protocols are different and the tolerance and expected sequelae are specific. Multidisciplinary meetings including adult and pediatric neuro-oncologists are warranted to share expertise. Since 2008, a weekly national web based conference was held in France. Any patient with the following criteria could be discussed: Adolescent and Young Adults aged between 15 and 25 years, and any adult with a pediatric type pathology, including medulloblastoma, germ cell tumors, embryonic tumors, ependymoma, pilocytic astrocytoma...
December 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27799929/the-high-prevalence-of-functional-complement-defects-induced-by-chemotherapy
#15
Mischa P Keizer, Angela M Kamp, Cathelijn Aarts, Judy Geisler, Huib N Caron, Marianne D van de Wetering, Diana Wouters, Taco W Kuijpers
INTRODUCTION: To date, oncology patients are more dependent on non-cellular host defense against pathogens due to intensive (chemo)therapy-related bone marrow suppression. Since data on complement functionality in oncology patients are limited, we aimed to investigate the innate complement function in relation to the type of malignancy and therapy in a longitudinal cohort of patients. METHODS: A large single-center, prospective non-intervention study was conducted, in which blood samples were taken from patients before, during, and after treatment with chemotherapy and/or subsequent admittance for (febrile) neutropenia...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27726252/whole-tumor-apparent-diffusion-coefficient-measurements-in-nephroblastoma-can-it-identify-blastemal-predominance
#16
Annemieke S Littooij, Neil J Sebire, Øystein E Olsen
PURPOSE: To explore the potential relation between whole-tumor apparent diffusion coefficient (ADC) parameters in viable parts of tumor and histopathological findings in nephroblastoma. MATERIALS AND METHODS: Children (n = 52) with histopathologically proven nephroblastoma underwent diffusion-weighted magnetic resonance imaging (MRI) (1.5T) before preoperative chemotherapy. Of these, 25 underwent an additional MRI after preoperative chemotherapy, shortly before resection...
October 11, 2016: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/27717499/-pediatric-ependymomas-current-diagnosis-and-therapy
#17
Didier Frappaz, Alexandre Vasiljevic, Pierre-Aurelien Beuriat, Claire Alapetite, Jacques Grill, Alexandru Szathmari, Cécile Faure-Conter
Ependymomas represent 10% of pediatric brain tumors. In the recent WHO 2016 classification, pathology is enriched by localization and molecular biology. Whatever the age, total removal by one or several looks when required remains a major prognostic factor. In children, focal radiation remains a standard, while the role of chemotherapy is matter of randomized studies. In infants, front line chemotherapy is the standard. Inclusion in the SIOP ependymoma II protocol is encouraged. In case of relapse, further surgery and radiation are advised, while inclusion in innovative trials including re-irradiation, and phase I-II should be encouraged...
October 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27673274/abstracts-from-the-48-th-congress-of-the-international-society-of-paediatric-oncology-siop-dublin-ireland-october-19-22-2016
#18
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27595352/epidemiology-of-adolescents-and-young-adults-with-cancer-in-europe
#19
Emmanuel Desandes, Daniel P Stark
To design the services for adolescents and young adults (AYAs) with cancer, we need to understand the patterns of disease and the other clinical and managerial challenges of the patient group. Cancer occurring between the ages of 15 and 39 years is 4 times less rare than cancer occurring during the first 15 years of life and consists of 2% of all invasive cancer in Europe, about 66,000 patients in Europe each year. AYAs have a unique distribution of cancer types, including the peak in incidence of Hodgkin lymphoma (HL) or germ cell tumors...
2016: Progress in Tumor Research
https://www.readbyqxmd.com/read/27585992/assessing-second-look-tumour-resectability-in-childhood-posterior-fossa-ependymoma-a-centralised-review-panel-and-staging-tool-for-future-studies
#20
Christopher P Millward, Conor Mallucci, Tim Jaspan, Donald Macarthur, Richard Heyward, Tim Cox, Kung Chong, Richard G Grundy
PURPOSE: To improve uniformity in radiological review/reporting and discussion of surgical resection status in the forthcoming SIOP Ependymoma II trial, a central review of imaging and resection status will be carried out prior to treatment stratification. We present a review of surgical decision-making from the UKCCSG/SIOP Ependymoma trial for very young children (<3 years) (Lancet Oncol 8:696-705, 2007) and propose a primary surgical staging system for residual disease that could be used for Ependymoma II...
November 2016: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
keyword
keyword
27879
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"